Roth MKM Keeps Their Buy Rating on Netlist (NLST)
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, De Silva is a 5-star analyst with an average return of 27.6% and a 50.71% success rate. De Silva covers the Technology sector, focusing on stocks such as Aeva Technologies, D-Wave Quantum, and Advanced Micro Devices.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Netlist with a $2.00 average price target.
Based on Netlist's latest earnings release for the quarter ending March 29, the company reported a quarterly revenue of $28.98 million and a GAAP net loss of $9.49 million. In comparison, last year the company earned a revenue of $35.81 million and had a GAAP net loss of $16.97 million
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
22 minutes ago
- Business Insider
Texas Sues Eli Lilly (LLY) for Allegedly Bribing Doctors to Prescribe Its Drugs
The U.S. State of Texas has launched a lawsuit against Eli Lilly (LLY), alleging that the pharmaceutical giant bribed doctors to prescribe its medications. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Texas Attorney General Ken Paxton announced the lawsuit on Aug. 12, claiming that Eli Lilly has been 'bribing' doctors and other medical providers to prescribe its medications for their patients. The state further claims that Eli Lilly bribed and illegally induced medical providers to prescribe its most profitable drugs, including the weight-loss medicine Zepbound. 'Big Pharma compromised medical decision-making by engaging in an illegal kickback scheme,' said Attorney General Paxton in announcing the lawsuit that seeks unspecified damages from Eli Lilly. The pharma company did not immediately respond publicly to the Texas lawsuit. Fraud and Abuse The lawsuit states that the Texas Attorney General aims to hold drug manufacturers accountable for fraud and abuse. Last year, the Texas Attorney General's office sued insulin manufacturers, including Eli Lilly, and pharmacy benefit managers alleging that they colluded to artificially raise the price of insulin. The lawsuit in Texas comes as LLY stock has been reeling after the company issued clinical trial results for its new weight-loss pill that came in below Wall Street's expectations. Following the trial results being made public, Eli Lilly's share price fell 15% for its biggest decline since the 2008 financial crisis. Is LLY Stock a Buy? The stock of Eli Lilly has a consensus Strong Buy rating among 21 Wall Street analysts. That rating is based on 17 Buy and four Hold recommendations issued in the last three months. The average LLY price target of $946.89 implies 51.35% upside from current levels.
Business Insider
an hour ago
- Business Insider
Is CSCO Stock a Buy? TipRanks AI Analyst Says Yes
Cisco Systems stock (CSCO) has earned an Outperform rating from TipRanks' A.I. Stock Analysis tool. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Cisco attracts strong interest from investors and Wall Street analysts. Notably, TipRanks' A.I. Analyst also gave Cisco a positive rating, signaling confidence in the stock's potential. The tool assigns an Outperform rating on Cisco stock with a solid score of 78. Meanwhile, the A.I. analyst assigns a price target of $73 to CSCO stock, implying an upside of over 3% from the current levels. For context, TipRanks' A.I. Stock Analysis provides automated, data-backed evaluations of stocks across key metrics, offering users a clear and concise view of a stock's potential. CSCO's Financial Strength Our AI analyst states that Cisco Systems demonstrates robust financial performance with strong profitability and cash flow, underpinning its stability in the communication equipment industry. It explains that the positive momentum aligns well with strategic growth in AI infrastructure and partnerships. Indeed, Cisco is uniquely positioned to facilitate AI deployment with its networking and security portfolios, as well as Silicon One. In addition, product innovation is a strength with the company announcing noteworthy new offerings, including a Unified Cloud Management platform and Hybrid Mesh Firewall. Overall, our AI egghead believes that Cisco is well-positioned for growth, though investors should remain mindful of external challenges such as tariffs and sector-specific headwinds. However, as can be seen above it is not all good news for Cisco. There are macroeconomic risks and some uncertainty around the stock given its failure to disclose AI revenue numbers. There are also some technical and valuation concerns – as seen below. The technical indicators suggest caution due to potential overbought conditions. Valuation remains a concern due to a higher P/E ratio, yet the company's dividend yield adds some long-term investment appeal. What Other Analysts Say David Vogt of UBS raised the firm's price target on Cisco to $74 from $70 and kept a Neutral rating on the shares. He said that increasing campus and data center demand should drive a beat when it reports Q4 earnings this week. JPMorgan analyst Samik Chatterjee raised the firm's price target on Cisco to $78 from $73 and kept an Overweight rating on the shares. The firm adjusted price targets in hardware and networking, saying it expects upside to second half of 2025 estimates from 'robust' cloud spending. However, underlying end market drivers for other customer verticals 'remain a watchpoint' as they exhibit more sensitivity to the economic environment. Is CSCO a Good Stock to Buy Now?
Business Insider
an hour ago
- Business Insider
‘Time to Wave Bye Bye,' Says Former Bull About Palantir Stock
Palantir (NASDAQ:PLTR) stock has been the subject of a mad scramble in recent years, as investors rush to ride the big data company's momentum. Its Q2 2025 earnings release once again topped expectations, with revenues surpassing the $1 billion mark for the first time. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. That milestone reflects more than just solid sales figures – it underscores how Palantir has carved out a distinctive niche, offering platforms that empower sovereign actors and government clients to dramatically increase efficiency and make faster, better-informed decisions in real time. Capitalizing on these gains, the company has continued to raise guidance and secure major deals, the latest being a U.S. Army contract worth up to $10 billion over the next decade. With revenue growth seemingly on autopilot, it might appear there's little reason for long-term holders to waver. But not everyone is convinced. One investor, known by the pseudonym Weebler, just can't justify PLTR's valuation – despite being a fan of the company's incredibly impressive moat. 'Even when we hold an almost stubborn conviction in any company's long-term potential, we must strive to be willing to set aside personal bias when new variables shift the risk-reward equation,' admits the 5-star investor. For Weebler, the problem lies in what the market is currently pricing in. A forward P/E multiple near 420x is 'beyond excessive,' and even dialing that back to a lofty 60x assumes Palantir will grow earnings tenfold in just two years, a feat without precedent for a large-cap tech company. 'That is beyond what even the most elite, high-growth tech companies have historically achieved at this scale,' emphasizes Weebler, adding that such assumptions also hinge on the share price holding steady. While acknowledging that irrational exuberance could keep fueling the rally in the short term, Weebler has decided it's time to step aside, cutting his rating on PLTR from Buy to Sell. 'The market seems to be getting irrationally greedy, and the growth expectations have stepped beyond what the most hypergrowth plays have ever achieved,' the investor concludes. (To watch Weebler Finance's track record, click here) There is clearly an abundance of caution on Wall Street as well. With 13 Hold ratings far outweighing 5 Buys and 2 Sells, PLTR holds a consensus Hold (i.e. Neutral) rating. Its 12-month average price target of $154.56 implies a 17% downside from current levels. (See PLTR stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
